The importance of inhibitor eradication in clinically complicated hemophilia A patients.

Abstract:

INTRODUCTION:Inhibitors against factor VIII (FVIII), which develop in around 20-30% of patients with severe hemophilia A, represent a significant complication of on-demand or prophylactic FVIII therapy. Currently, the main treatment option for inhibitor patients is eradication using immune tolerance induction (ITI) therapy. Areas covered: This article reviews inhibitor eradication in clinically complicated hemophilia A patients. The benefits and disadvantages of ITI therapy are discussed, with reference to the new nonfactor replacement agents such as emicizumab, which are becoming available. Expert commentary: At present, ITI therapy is the method of choice for all inhibitor patients, but as alternative treatment options become increasingly available, this may change in the future. Despite the development of nonfactor replacement agents, ITI therapy is likely to maintain a key role in the management of inhibitor patients, although changes in ITI therapy regimens including the timing of ITI initiation, the dosing regimen, the management of thrombotic risk or safety, laboratory assessment of ITI outcomes, and maintenance treatment after ITI success, may be necessary.

journal_name

Expert Rev Hematol

authors

Oldenburg J,Young G,Santagostino E,Escuriola Ettingshausen C

doi

10.1080/17474086.2018.1521718

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

857-862

issue

11

eissn

1747-4086

issn

1747-4094

journal_volume

11

pub_type

杂志文章,评审
  • Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

    abstract::Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.932687

    authors: Al-Hussaini M,DiPersio JF

    更新日期:2014-08-01 00:00:00

  • Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.

    abstract:INTRODUCTION:Hodgkin's lymphoma (HL) is largely a curable disease with excellent prognosis. The standard of care in patients with relapsed disease has been to try salvage chemotherapy followed by an autologous stem cell transplantation (ASCT). Managing the patients who relapse after ASCT, is challenging. With the appro...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1449637

    authors: Kallam A,Armitage JO

    更新日期:2018-04-01 00:00:00

  • Safety issues and management of toxicities associated with new treatments for multiple myeloma.

    abstract:INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2017.1284584

    authors: Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

    更新日期:2017-03-01 00:00:00

  • Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review.

    abstract:INTRODUCTION:Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), which not only improved outcomes for patients but also increased complexity of treatment decisions. The approvals are based on randomized studies of novel agent...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1804356

    authors: Sanchez L,Barley K,Richter J,Franz J,Cho HJ,Jagannath S,Madduri D,Parekh S,Richard S,Chari A

    更新日期:2020-09-01 00:00:00

  • Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.

    abstract::β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.13.24

    authors: Breda L,Rivella S,Zuccato C,Gambari R

    更新日期:2013-06-01 00:00:00

  • Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding.

    abstract::Introduction: Oral anticoagulants (OACs) are established treatments to reduce thromboembolic risk in patients with atrial fibrillation (AF). Due to their mechanisms of action, they are associated with increased bleeding risk. Evaluation with bleeding risk scores may be useful to identify patients at high risk. However...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1647779

    authors: Kozieł M,Ding WY,Kalarus Z,Lip GYH

    更新日期:2019-10-01 00:00:00

  • Gonadal dysfunction in adult male patients with thalassemia major: an update for clinicians caring for thalassemia.

    abstract:INTRODUCTION:Hypogonadism is the most frequently reported endocrine complication, affecting 40%-80% of thalassemia major (TM) patients. The prevalence and severity of hypogonadism in TM varies among studies, depending on patients' age, genotype, transfusion frequency and starting age and efficiency of iron chelation. A...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1398080

    authors: De Sanctis V,Soliman AT,Elsedfy H,Di Maio S,Canatan D,Soliman N,Karimi M,Kattamis C

    更新日期:2017-12-01 00:00:00

  • Primary mediastinal lymphoma: diagnosis and treatment options.

    abstract::Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a diffuse proliferation of medium-to-large B cells associated with...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.994604

    authors: Martelli M,Di Rocco A,Russo E,Perrone S,Foà R

    更新日期:2015-04-01 00:00:00

  • Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.

    abstract::The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.7

    authors: Ninan MJ,Morrison VA

    更新日期:2009-04-01 00:00:00

  • Point mutations which should not be overlooked in Hb H disease.

    abstract:BACKGROUND:Hb H disease is an alpha-thalassemia (α-thal) syndrome characterized by chronic hemolytic anemia that occurs when three of total four α-globin genes lost their function due to completely deletions or different kind of mutations. OBJECTIVE:We here described 66 patients who have been diagnosed for Hb H diseas...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/17474086.2016.1107470

    authors: Farashi S,Bayat N,Vakili S,Faramarzi Garous N,Ashki M,Imanian H,Najmabadi H,Azarkeivan A

    更新日期:2016-01-01 00:00:00

  • FLT3 inhibitors in acute myeloid leukemia.

    abstract::The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute myeloid leukemias (AMLs) and are associated with a distinctly poor clinical outcome for patients. There are now several class...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.1.2.153

    authors: el-Shami K,Stone RM,Smith BD

    更新日期:2008-12-01 00:00:00

  • Mobilization of hematopoietic stem cells into the peripheral blood.

    abstract::Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.54

    authors: Damon LE,Damon LE

    更新日期:2009-12-01 00:00:00

  • Bronchial myeloid sarcoma with concurrent Aspergillus fumigatus infection in a patient presenting with hemoptysis.

    abstract::Myeloid sarcoma (MS) is an extramedullary myeloid neoplasm characterized by proliferation of myeloblasts which can occur in any organ or site. Bronchial and pulmonary involvement, however, is uncommon. We describe a case of bronchial MS in an 81-year-old female with a history of high-grade myelodysplastic syndrome; sh...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/17474086.2015.1044747

    authors: Vennepureddy A,Valecha G,Murukutla S,Hussein S,Terjanian T

    更新日期:2015-08-01 00:00:00

  • Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?

    abstract::Major advances have significantly improved the outcome of mantle cell lymphoma (MCL). Incorporation of rituximab to CHOP regimen, the adoption of high dose cytarabine with frontline autologous stem cell transplantation in young patients, maintenance rituximab or bortezomib based chemotherapy in elderly patients, impro...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1134309

    authors: El Halabi L,Ghez D,Ribrag V

    更新日期:2016-03-01 00:00:00

  • Prognostic tools in follicular lymphomas.

    abstract::Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.34

    authors: Luminari S,Cox MC,Montanini A,Federico M

    更新日期:2009-10-01 00:00:00

  • Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.

    abstract::Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1142370

    authors: Figueiredo L,Cole PD,Drachtman RA

    更新日期:2016-03-01 00:00:00

  • The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

    abstract:INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1437345

    authors: Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

    更新日期:2018-03-01 00:00:00

  • Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

    abstract::In chronic lymphocytic leukemia (CLL), the most prevalent lymphoid malignancy in western countries, patients have a median age at diagnosis of 72 years. In the last few years, there has been remarkable progress in understanding the biology of CLL, the detection of molecular prognostic factors and the development of mo...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2013.814845

    authors: Molica S,Brugiatelli M,Morabito F,Ferrara F,Iannitto E,Di Renzo N,Capalbo S,Musto P,Di Raimondo F

    更新日期:2013-08-01 00:00:00

  • Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.

    abstract::Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.963048

    authors: Robak T

    更新日期:2014-12-01 00:00:00

  • Eltrombopag for the treatment of immune thrombocytopenia.

    abstract::Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated plat...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.11.25

    authors: Cheng G

    更新日期:2011-06-01 00:00:00

  • The gut microbiota - a modulator of endothelial cell function and a contributing environmental factor to arterial thrombosis.

    abstract::Introduction: There is emerging evidence linking the commensal gut microbiota with the development of cardiovascular disease and arterial thrombosis. In immunothrombosis, the host clotting system protects against the dissemination of invading microbes, not considering the huge number of microbes that interact with hos...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1627191

    authors: Formes H,Reinhardt C

    更新日期:2019-07-01 00:00:00

  • Factor VIII therapy for hemophilia A: current and future issues.

    abstract::Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic u...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.899896

    authors: Aledort L,Ljung R,Mann K,Pipe S

    更新日期:2014-06-01 00:00:00

  • An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.

    abstract::Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, consumption thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, the specific von Willebrand factor (VWF)-cl...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1611423

    authors: Joly BS,Coppo P,Veyradier A

    更新日期:2019-06-01 00:00:00

  • Polyphosphates: a link between platelet activation, intrinsic coagulation and inflammation?

    abstract::Early evidence has already shown that activated platelets play a role in the intrinsic pathway of coagulation, but the mechanism remained unclear. The finding that the dense granules of platelets contain polyphosphate (polyP), which has procoagulant effects, resolved this missing link between activated platelets and c...

    journal_title:Expert review of hematology

    pub_type: 评论,杂志文章

    doi:10.1586/ehm.10.26

    authors: van der Meijden PE,Heemskerk JW

    更新日期:2010-06-01 00:00:00

  • Iliopsoas hematomas in people with hemophilia: diagnosis and treatment.

    abstract:INTRODUCTION:Iliopsoas muscle hemorrhage in patients with hemophilia is a serious complication with relevant related morbidity. AREAS COVERED:A Cochrane Library and PubMed (MEDLINE) search of studies related to iliopsoas hematomas in hemophilia was analyzed. Pain in the hip joint area and femoral nerve involvement in ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1787146

    authors: Rodriguez-Merchan EC,De la Corte-Rodriguez H

    更新日期:2020-08-01 00:00:00

  • Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.

    abstract::Sickle cell disease (SCD) is a severe genetic disorder of hemoglobin causing vaso-occlusion. Patients suffer severe anemia, strokes, renal failure, pulmonary compromise and shortened life expectancy. Over 90,000 people in the USA have SCD, and the options for therapy are limited and only partially effective. With the ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.12.20

    authors: Okam MM,Ebert BL

    更新日期:2012-06-01 00:00:00

  • One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic

    abstract::Key paper evaluation: Craddock C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019; 37: 580-8. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only potentially cura...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1635005

    authors: Bewersdorf JP,Stahl M,Zeidan AM

    更新日期:2019-08-01 00:00:00

  • Incorporating placental tissue in cord blood banking for stem cell transplantation.

    abstract:INTRODUCTION:Human term placenta is comprised of various tissues from which different cells can be obtained, including hematopoietic stem cells and mesenchymal stem/stromal cells (MSCs). Areas covered: This review will discuss the possibility to incorporate placental tissue cells in cord blood banking. It will discuss ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1483717

    authors: Teofili L,Silini AR,Bianchi M,Valentini CG,Parolini O

    更新日期:2018-08-01 00:00:00

  • Immunotherapy for the treatment of Hodgkin lymphoma.

    abstract:INTRODUCTION:Most patients with Hodgkin lymphoma (HL) enjoy durable remissions following front-line treatment but 30% of patients are refractory or relapse after first line therapy. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) can cure an additional 50-55% of relapsing patients but new t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1313701

    authors: Donato EM,Fernández-Zarzoso M,De La Rubia J

    更新日期:2017-05-01 00:00:00

  • CD43 in the malignant flow cytometry laboratory in 2020.

    abstract::Objectives: CD43 can be useful in routine flow cytometry. We conducted a systematic review aiming to describe when CD43 is used by flow cytometry in malignant hematology and to determine its value in these settings. Methods: Systematic review of MEDLINE (search 'CD43' AND 'flow cytometry,' starting in 2010). Results: ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2021.1856653

    authors: Sorigue M

    更新日期:2021-01-01 00:00:00